FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia

Blood Cancer Journal

Volumn 1, Issue 11, 2011, Pages

  Passlic Z ^a,b   Greif, P A ^a,b   Jurinovic V ^c   Mulaw, M ^a,b   Kakadia, P M ^a   Tizazu, B ^a,b   Archangelo, Leticia Fröhlich ^a,b   Krause, A ^a,b   Bohlander, S K ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

AF11; CALM; FHL2

Indexed keywords

AMINO ACID; CLATHRIN ASSEMBLY LYMPHOID MYELOID LEUKEMIA PROTEIN; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; LIM DOMAIN PROTEIN 2; LIM PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KARYOTYPE; LEUKEMOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; TRANSCRIPTION INITIATION;

EID: 84863905940     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.40     Document Type: Article

References (60)

1. Rowley JD. The critical role of chromosome translocations in human leukemias. Annu Rev Genet 1998; 32: 495-519. (Pubitemid 29045322)
2. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372: 143-149. (Pubitemid 24347832)
3. Dreyling MH, Martinez-Climent JA, Zheng M, Mao J, Rowley JD, Bohlander SK. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc Natl Acad Sci USA 1996; 93: 4804-4809. (Pubitemid 26162832)
4. Dreyling MH, Schrader K, Fonatsch C, Schlegelberger B, Haase D, Schoch C et al. MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. Blood 1998; 91: 4662-4667. (Pubitemid 28270315)
5. Bohlander SK, Muschinsky V, Schrader K, Siebert R, Schlegelberger B, Harder L et al. Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. Leukemia 2000; 14: 93-99. (Pubitemid 30068378)
6. Chaplin T, Ayton P, Bernard OA, Saha V, Della Valle V, Hillion J et al. A novel class of zinc finger/leucine zipper genes identified from the molecular cloning of the t(10;11) translocation in acute leukemia. Blood 1995; 85: 1435-1441.
7. Perrin L, Bloyer S, Ferraz C, Agrawal N, Sinha P, Dura JM. The leucine zipper motif of the Drosophila AF10 homologue can inhibit PRE-mediated repression: implications for leukemogenic activity of human MLL-AF10 fusions. Mol Cell Biol 2003; 23: 119-130. (Pubitemid 36008506)
8. Greif PA, Tizazu B, Krause A, Kremmer E, Bohlander SK. The leukemogenic CALM/AF10 fusion protein alters the subcellular localization of the lymphoid regulator Ikaros. Oncogene 2008; 27: 2886-2896. (Pubitemid 351620446)
9. Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocyticcoated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell 1999; 10: 2687-2702. (Pubitemid 29393520)
10. Archangelo LF, Glasner J, Krause A, Bohlander SK. The novel CALM interactor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10. Oncogene 2006; 25: 4099-4109. (Pubitemid 44024872)
11. Ford MG, Pearse BM, Higgins MK, Vallis Y, Owen DJ, Gibson A et al. Simultaneous binding of PtdIns(4, 5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science 2001; 291: 1051-1055. (Pubitemid 32157415)
12. Meyerholz A, Hinrichsen L, Groos S, Esk PC, Brandes G, Ungewickell EJ. Effect of clathrin assembly lymphoid myeloid leukemia protein depletion on clathrin coat formation. Traffic 2005; 6: 1225-1234. (Pubitemid 41632272)
13. Kim JA, Kim HL. Cell-free expression and functional reconstitution of CALM in clathrin assembly. Exp Mol Med 2001; 33: 89-94.
14. Klebig ML, Wall MD, Potter MD, Rowe EL, Carpenter DA, Rinchik EM. Mutations in the clathrin-assembly gene Picalm are responsible for the hematopoietic and iron metabolism abnormalities in fit1 mice. Proc Natl Acad Sci USA 2003; 100: 8360-8365. (Pubitemid 36842550)
15. Deshpande AJ, Cusan M, Rawat VP, Reuter H, Krause A, Pott C et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/ AF10-positive leukemia. Cancer Cell 2006; 10: 363-374. (Pubitemid 44693467)
16. Caudell D, Zhang Z, Chung YJ, Aplan PD. Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice. Cancer Res 2007; 67: 8022-8031. (Pubitemid 47395136)
17. Johannessen M, Moller S, Hansen T, Moens U, Van Ghelue M. The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci 2006; 63: 268-284. (Pubitemid 43202310)
18. Wei Y, Renard C-A, Labalette C, Wu Y, Lévy L, Neuveut C et al. Identification of the LIM protein FHL2 as a coactivator of bcatenin. J Biol Chem 2003; 278: 5188-5194. (Pubitemid 36801031)
19. Labalette C, Renard C-A, Neuveut C, Buendia M-A, Wei Y. Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and {beta}-catenin. Mol Cell Biol 2004; 24: 10689-10702. (Pubitemid 39603127)
20. Kleiber K, Strebhardt K, Martin BT. The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res 2007; 27: 55-61.
21. Gabriel B, Fischer DC, Orlowska-Volk M, zur Hausen A, Schule R, Muller JM et al. Expression of the transcriptional coregulator FHL2 in human breast cancer: a clinicopathologic study. J Soc Gynecol Invest 2006; 13: 69-75. (Pubitemid 43003570)
22. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66: 11341-11347. (Pubitemid 46009965)
23. Gabriel B, Mildenberger S, Weisser CW, Metzger E, Gitsch G, Schule R et al. Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res 2004; 24: 921-927. (Pubitemid 38625040)
24. Wang J, Yang Y, Xia HH, Gu Q, Lin MC, Jiang B et al. Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 2007; 132: 1066-1076. (Pubitemid 46440856)
25. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008; 112: 4193-4201.
26. Johnson T. Bayesian method for gene detection and mapping, using a case and control design and DNA pooling. Biostat 2007; 8: 546-565.
27. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat 1996; 5: 299-314.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
29. Rothbauer U, Zolghadr K, Muyldermans S, Schepers A, Cardoso MC, Leonhardt H. A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol Cell Proteomics 2008; 7: 282-289. (Pubitemid 351298442)
30. Müller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A et al. FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J 2000; 19: 359-369. (Pubitemid 30072606)
31. Okada Y, Jiang Q, Lemieux M, Jeannotte L, Su L, Zhang Y. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol 2006; 8: 1017-1024. (Pubitemid 44314734)
32. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005; 121: 167-178. (Pubitemid 40546386)
33. Lange S, Auerbach D, McLoughlin P, Perriard E, Schafer BW, Perriard J-C et al. Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2. J Cell Sci 2002; 115: 4925-4936. (Pubitemid 36054644)
34. Ng EK, Chan KK, Wong CH, Tsui SK, Ngai SM, Lee SM et al. Interaction of the heart-specific LIM domain protein, FHL2, with DNA-binding nuclear protein, hNP220. J Cell Biochem 2002; 84: 556-566.
35. Coghill ID, Brown S, Cottle DL, McGrath MJ, Robinson PA, Nandurkar HH et al. FHL3 is an actin-binding protein that regulates alpha-actinin-mediated actin bundling: FHL3 localizes to actin stress fibers and enhances cell spreading and stress fiber disassembly. J Biol Chem 2003; 278: 24139-24152. (Pubitemid 36830250)
36. Kobayashi S, Shibata H, Yokota K, Suda N, Murai A, Kurihara I et al. FHL2, UBC9, and PIAS1 are novel estrogen receptor alphainteracting proteins. Endocr Res 2004; 30: 617-621. (Pubitemid 40070141)
37. Yang Y, Hou H, Haller EM, Nicosia SV, Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J 2005; 24: 1021-1032. (Pubitemid 40470150)
38. Wixler V, Geerts D, Laplantine E, Westhoff D, Smyth N, Aumailley M et al. The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes. J Biol Chem 2000; 275: 33669-33678.
39. De Camilli P, Chen H, Hyman J, Panepucci E, Bateman A, Brunger AT. The ENTH domain. FEBS Lett 2002; 513: 11-18. (Pubitemid 34242972)
40. Evans PR, Owen DJ. Endocytosis and vesicle trafficking. Curr Opin Struct Biol 2002; 12: 814-821. (Pubitemid 36009499)
41. Stahelin RV, Long F, Peter BJ, Murray D, De Camilli P, McMahon HT et al. Contrasting membrane interaction mechanisms of AP180 N-terminal homology (ANTH) and epsin N-terminal homology (ENTH) domains. J Biol Chem 2003; 278: 28993-28999. (Pubitemid 36935811)
42. Kalthoff C, Alves J, Urbanke C, Knorr R, Ungewickell EJ. Unusual structural organization of the endocytic proteins AP180 and epsin 1. J Biol Chem 2002; 277: 8209-8216. (Pubitemid 34968277)
43. Samson T, Smyth N, Janetzky S, Wendler O, Muller JM, Schule R et al. The LIM-only proteins FHL2 and FHL3 interact with alphaand beta-subunits of the muscle alpha7beta1 integrin receptor. J Biol Chem 2004; 279: 28641-28652. (Pubitemid 38900147)
44. Van Nhieu GT, Krukonis ES, Reszka AA, Horwitz AF, Isberg RR. Mutations in the cytoplasmic domain of the integrin beta1 chain indicate a role for endocytosis factors in bacterial internalization. J Biol Chem 1996; 271: 7665-7672. (Pubitemid 26107048)
45. Hill AA, Riley PR. Differential regulation of Hand1 homodimer and Hand1-E12 heterodimer activity by the cofactor FHL2. Mol Cell Biol 2004; 24: 9835-9847. (Pubitemid 39458811)
46. Labalette C, Nouet Y, Sobczak-Thepot J, Armengol C, Levillayer F, Gendron MC et al. The LIM-only protein FHL2 regulates cyclin D1 expression and cell proliferation. J Biol Chem 2008; 283: 15201-15208.
47. Scholl FA, McLoughlin P, Ehler E, de Giovanni C, Schafer BW. Dral is a P53-responsive gene whose four and a half Lim domain protein product induces apoptosis. J Cell Biol 2000; 151: 495-506.
48. Shaknovich R, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S et al. The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Mol Cell Biol 1998; 18: 5533-5545. (Pubitemid 28388136)
49. Barna M, Hawe N, Niswander L, Pandolfi PP. Plzf regulates limb and axial skeletal patterning. Nat Genet 2000; 25: 166-172. (Pubitemid 30394986)
50. McLoughlin P, Ehler E, Carlile G, Licht JD, Schäfer BW. The LIMonly protein DRAL/FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger protein. J Biol Chem 2002; 277: 37045-37053.
51. Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993; 12: 1161-1167. (Pubitemid 23095865)
52. Dik WA, Brahim W, Braun C, Asnafi V, Dastugue N, Bernard OA et al. CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. Leukemia 2005; 19: 1948-1957. (Pubitemid 41554004)
53. Lin YH, Kakadia PM, Chen Y, Li YQ, Deshpande AJ, Buske C et al. Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10-positive leukemias. Blood 2009; 114: 651-658.
54. Chen D, Xu W, Bales E, Colmenares C, Conacci-Sorrell M, Ishii S et al. SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res 2003; 63: 6626-6634. (Pubitemid 37322940)
55. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11: 162-171.
56. Qian Z, Mao L, Fernald AA, Yu H, Luo R, Jiang Y et al. Enhanced expression of FHL2 leads to abnormal myelopoiesis in vivo. Leukemia 2009; 23: 1650-1657.
57. Schoch C, Kohlmann A, Schnittger S, Brors B, Dugas M, Mergenthaler S et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci USA 2002; 99: 10008-10013. (Pubitemid 34831163)
58. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333. (Pubitemid 28452973)
59. Killick S, Matutes E, Powles RL, Min T, Treleaven JG, Rege KP et al. Acute erythroid leukemia (M6): outcome of bone marrow transplantation. Leuk Lymphoma 1999; 35: 99-107. (Pubitemid 29454407)
60. Hamidouche Z, Hay E, Vaudin P, Charbord P, Schule R, Marie PJ et al. FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/betacatenin signaling-dependent Runx2 expression. FASEB J 2008; 22: 3813-3822.